PCM
JSPR icon

Penserra Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Penserra Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-671
Closed -$12K – 1089
2022
Q2 		$12K Buy
671
+231
+53% +$6.58K ﹤0.01% 1206
2022
Q1 		$15K Buy
440
+167
+61% +$7.53K ﹤0.01% 1327
2021
Q4 		$21K Buy
+273
New +$25.5K ﹤0.01% 1232

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FIM
Fernwood Investment Management Quincy, Massachusetts $288M AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Penserra Capital Management's JSPR Position: Q3 2022 in Review

Penserra Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2022, closing a stake of 671 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in JSPR in Q4 2021 and held it in 3 quarters. The position peaked at $21K in Q4 2021. 23 funds tracked by Wall St. Rank hold JSPR as of Q3 2022.

  • Penserra Capital Management reported no remaining Jasper Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 671 Jasper Therapeutics shares in Q3 2022, an estimated $12K.
  • Penserra Capital Management first reported a position in Jasper Therapeutics in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's Jasper Therapeutics position peaked at $21K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.